Analysts Set $33.00 Target Price for SpringWorks Therapeutics (NASDAQ:SWTX)

Share on StockTwits

Shares of SpringWorks Therapeutics (NASDAQ:SWTX) have received an average broker rating score of 1.00 (Strong Buy) from the four brokers that cover the stock, Zacks Investment Research reports. Four research analysts have rated the stock with a strong buy rating.

Brokerages have set a 12-month consensus price target of $33.00 for the company and are predicting that the company will post ($0.36) EPS for the current quarter, according to Zacks. Zacks has also assigned SpringWorks Therapeutics an industry rank of 56 out of 255 based on the ratings given to its competitors.

A number of research analysts have weighed in on the stock. Goldman Sachs Group assumed coverage on shares of SpringWorks Therapeutics in a research note on Tuesday, October 8th. They issued a “buy” rating and a $37.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $34.00 price objective on shares of SpringWorks Therapeutics in a research note on Tuesday, December 10th. JPMorgan Chase & Co. assumed coverage on shares of SpringWorks Therapeutics in a research note on Tuesday, October 8th. They issued an “overweight” rating and a $32.00 price objective on the stock. Cowen assumed coverage on shares of SpringWorks Therapeutics in a research note on Tuesday, October 8th. They issued an “outperform” rating on the stock. Finally, Wedbush assumed coverage on shares of SpringWorks Therapeutics in a research note on Tuesday, October 8th. They issued an “outperform” rating and a $33.00 price objective on the stock.

Shares of NASDAQ SWTX opened at $28.90 on Tuesday. SpringWorks Therapeutics has a 12-month low of $17.02 and a 12-month high of $30.42. The business’s fifty day moving average is $21.42.

SpringWorks Therapeutics (NASDAQ:SWTX) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($1.77) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($1.30). On average, analysts predict that SpringWorks Therapeutics will post -2.44 EPS for the current year.

In other news, major shareholder Bain Capital Life Sciences Inv bought 150,000 shares of the stock in a transaction dated Tuesday, September 17th. The stock was bought at an average price of $18.00 per share, for a total transaction of $2,700,000.00. Also, Director Stephen P. Squinto bought 275,000 shares of the stock in a transaction dated Tuesday, September 17th. The stock was purchased at an average price of $18.00 per share, with a total value of $4,950,000.00.

A hedge fund recently bought a new stake in SpringWorks Therapeutics stock. Millennium Management LLC bought a new stake in SpringWorks Therapeutics (NASDAQ:SWTX) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 403,613 shares of the company’s stock, valued at approximately $8,750,000. Millennium Management LLC owned about 0.94% of SpringWorks Therapeutics at the end of the most recent reporting period. Institutional investors own 72.13% of the company’s stock.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a clinical-stage biopharmaceutical company, acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its advanced product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase 3 clinical trials for the treatment of desmoid tumors.

Featured Article: The role of implied volatility with call option volume

Get a free copy of the Zacks research report on SpringWorks Therapeutics (SWTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for SpringWorks Therapeutics (NASDAQ:SWTX)

Receive News & Ratings for SpringWorks Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SpringWorks Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Actual Experience  Reaches New 52-Week Low at $76.00
Actual Experience Reaches New 52-Week Low at $76.00
Ten Entertainment Group  Reaches New 12-Month High at $324.00
Ten Entertainment Group Reaches New 12-Month High at $324.00
TNR Gold  Sets New 52-Week Low at $0.02
TNR Gold Sets New 52-Week Low at $0.02
Cargojet  Sets New 52-Week High at $115.00
Cargojet Sets New 52-Week High at $115.00
Billington  Sets New 52-Week High at $396.00
Billington Sets New 52-Week High at $396.00
Keystone Investment Trust  Reaches New 52-Week High at $1,820.00
Keystone Investment Trust Reaches New 52-Week High at $1,820.00


© 2006-2020 Ticker Report